TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
The presentation details are as follows:
- Title: TG-1601 is a novel
BETinhibitor with strong binding affinity and long-lasting effect in pre-clinical models
o Abstract Number: 5790
o Date and Time:
Wednesday, April 18, 2018 8:00 AM - 12:00 PM (CT)
o Session Category/Title: Experimental and Molecular Therapeutics/ Canonical Targets 2
McCormick Place South, Exhibit Hall A, Poster Section 36
o Poster Board Number: 16
A copy of the above referenced abstract can be viewed online through the AACR meeting website at www.aacr.org. Following the presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, the combination of which is referred to as ‘U2', are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.
Some of the statements included in this press release or in the abstract, particularly those anticipating future clinical trials, attributes, business prospects and/or potential use of TG-1601, the company’s
SVP, Corporate Communications
Source: TG Therapeutics, Inc.